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Abstract
Background: The intravenous use of polymyxins has been considered to be associated with
considerable nephrotoxicity and neurotoxicity. For this reason, the systemic administration of
polymyxins had been abandoned for about 20 years in most areas of the world. However, the
problem of infections due to multidrug-resistant (MDR) Gram-negative bacteria such us
Pseudomonas aeruginosa and Acinetobacter baumanniii has led to the re-use of polymyxins. Our
objective was to study the toxicity of prolonged intravenous administration of colistin (polymyxin
E).
Methods: An observational study of a retrospective cohort at "Henry Dunant" Hospital, a 450-
bed tertiary care center in Athens, Greece, was undertaken.
Patients who received intravenous colistin for more than 4 weeks for the treatment of multidrug
resistant Gram-negative infections were included in the study. Serum creatinine, blood urea, liver
function tests, symptoms and signs of neurotoxicity were the main outcomes studied.
Results: We analyzed data for 19 courses of prolonged intravenous colistin [mean duration of
administration (± SD) 43.4 (± 14.6) days, mean daily dosage (± SD) 4.4 (± 2.1) million IU, mean
cumulative dosage (± SD) 190.4 (± 91.0) million IU] in 17 patients. The median creatinine value
increased by 0.25 mg/dl during the treatment compared to the baseline (p < 0.001) but returned
close to the baseline at the end of treatment (higher by 0.1 mg/dl, p = 0.67). No apnea or other
evidence of neuromuscular blockade was noted in any of these patients who received prolonged
treatment with colistin.
Conclusions: No serious toxicity was observed in this group of patients who received prolonged
intravenous colistin. Colistin should be considered as a therapeutic option in patients with
infections due to multidrug resistant Gram-negative bacteria.
Background
The worldwide spread of the problem of infections due to
Gram-negative bacteria such us Pseudomonas aeruginosa
and Acinetobacter baumannii resistant to most classes of
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antimicrobial agents has made the medical community to
rethink of colistin, an old, basically abandoned for the last
two decades antibiotic. Intravenous colistin (polymyxin
E) has been used in the industrialized countries during the
last years mainly in patients with cystic fibrosis infected
with Pseudomonas aeruginosa resistant to other available
antimicrobial classes [1]. Excluding this population, the
agent has been infrequently used during the last two dec-
ades because of major concerns about nephrotoxicity and
neurotoxicity [2].
Several reports during the early years of use of the medica-
tion, mainly in the decade 1960 to 1969 left the medical
community with the impression that the medication is
very toxic [3,4]. However, the recent experience of several
clinicians worldwide with the use of the medication has
not verified the old reports about the serious or common
toxicity of colistin [5-8]. We analysed data of a group of
patients who received colistin for more than four weeks to
investigate further the concerns about the toxicity of the
medication.
Methods
Design of the study-patient selection
Patients who received intravenous colistin from 1/Octo-
ber/2000 to 31/January/2004 at "Henry Dunant" Hospi-
tal, a 450-bed tertiary care center in Athens, Greece, were
identified by the pharmacy electronic databases. All
patients who were found to have received intravenous col-
istin for more than four weeks continuously, or in two
courses of colistin but with no more than seven days inter-
ruption between the courses were included in this study.
Administration of intravenous colistin in two courses for
more than four weeks in each course were studied as two
different units in the analysis of toxicity, if there was more
than one month colistin-free period between the two
courses. One milligram of the colistin formulations used
is approximately equal to 12.500 IU (Colomycin, Forest
Laboratories®, Kent, UK or Colistin, Norma®, Athens,
Greece). The study was approved by the Institutional
Review Board (IRB) of the hospital.
Definitions of infections
Diagnosis of pneumonia required two or more serial chest
radiographs with at least one of the following: new or pro-
gressive and persistent infiltrate, consolidation, cavita-
tion, or pleural effusion. In addition, patients must have
had fever >38°C with no other recognized cause, or
abnormal white blood cell count [leukopenia (< 4000
WBC/mm3) or leukocytosis (= 12.000 WBC/mm3)], and
at least two of the following: new onset of purulent spu-
tum or change in character of sputum, increased respira-
tory secretions or increased suctioning requirements, new
onset or worsening of cough or dyspnea or tachypnea,
rales or bronchial breath sounds, or worsening gas
exchange [9].
Bacteremia required either growth of a recognized patho-
gen from one or more blood specimen cultures or at least
one of the following signs or symptoms: fever (>38°C),
chills, or hypotension and at least one of the following: a)
common skin contaminant (e.g., diphtheroids, Bacillus
sp., Propionibacterium sp., coagulasenegative staphyloco-
cci, or micrococci) grown from two or more blood cul-
tures drawn on separate occasions or b) common skin
contaminant (e.g., diphtheroids, Bacillus  sp.,  Propioni-
bactαium sp., coagulase-negative staphylococci, or micro-
cocci) grown from at least one blood culture from a
patient with an intravascular line and physician- insti-
tuted antimicrobial therapy [9].
Infections at other body sites or fluids, such as urinary
tract infections and surgical site infections were defined
based on guidelines from the Centers for Disease Control
and Prevention [9]. Clinical specimens of all body sites
were considered when defining the etiologic microbio-
logic agent of the infection.
Data collection-entry
Data for several variables including demographic and
clinical information as well as results of laboratory and
imaging tests were collected and entered in a computer
database. All available results of renal function tests
(serum creatinine, urea, creatinine clearance, urinalysis),
liver function tests (SGPT, SGOT, alkaline phosphatase, γ-
GT, bilirubin), creatine phosphokinase (CPK) during the
course of colistin treatment and at hospital discharge were
collected.
Data analysis
Creatinine values at the beginning of colistin treatment
were compared with the maximum value of creatinine
during therapy as well as with the creatinine value at the
end of treatment using a non-parametric test (Wilcoxon).
The data analysis was performed using SPSS and S-plus
software.
Results
Study population
During the period from 1/October/2000 to 31/January/
2004, 152 patients received intravenous colistin. Data
about the efficacy of the medication were analysed and
reported elsewhere [5]. In this report, we present detailed
data regarding the toxicity of colistin in a subgroup of 17
patients who received more than four weeks of intrave-
nous colistin. Table 1 describes various characteristics of
this group of patients including demographic and clinical
data, such as comorbidity, site of infection, and responsi-
ble pathogens. Two patients received two prolongedBMC Infectious Diseases 2005, 5:1 http://www.biomedcentral.com/1471-2334/5/1
Page 3 of 8
(page number not for citation purposes)
courses of intravenous colistin each with more than one
month colistin-free period between the courses. Subse-
quently, there were 19 courses of prolonged colistin for
the analysis of toxicity. Among these 19 courses, the
administration of intravenous colistin was without inter-
ruption in 15 courses, while there was interruption of col-
istin administration in 2 courses for two days,
interruption in 1 course for 3 days, and interruption in 1
Table 1: Demographic and clinical features of patients managed with prolonged intravenous colistin for infections caused by 
multidrug-resistant Gram-negative bacteria.
Characteristics of patients Median (range) n (%)
Demographic
Age, years [median (range)] 51 (18 – 79)
Sex, male 12/17 (70%)
APACHE II score
On admission to ICU [median (range)] 14 (7 – 35)
On 1st day of colistin treatment [median (range)] 14 (6 – 22)
Comorbidity
Malignancy 2/17 (11%)
Hemodialysis 2/17 (11%)
Urogenital disorders 3/17 (18%)
Heart dysfunction 5/17 (29%)
Diabetes mellitus 5/17 (29%)
Lung dysfunction 5/17 (29%)
Liver failure 1/17 (6%)
Hematological disorders 3/17 (18%)
Neurological disorders 8/17 (47%)
Neuropathy/myopathy 4/17 (23%)
Trauma 7/17 (41%)
Transfusion 15/17 (88%)
Prior hospitalization 12/17 (70%)
Prior surgery 14/17 (82%)
Elective 9/14 (64%)
Emergency 5/14 (36%)
Prosthetic material 11/17 (64%)
Catheters/Invasive devices
Tracheostomy 14/17 (82%)
CSF drainage 5/17 (29%)
Prior medications
Prior antibiotic use 17/17 (100%)
Prior antifungal use 8/17 (47%)
Anti-tumor treatment 0/17 (0%)
Cortisone treatment 9/17 (53%)
Duration of hospitalization (days) [median (range)] 152 (29 – 591)
Duration of stay in ICU (days) [median (range)] 70 (22 – 134)
Site of infection*
Pneumonia 13/19 (68%)
Bacteremia 1/19 (5%)
Urinary tract infection 2/19 (11%)
Meningitis 2/19 (11%)
Surgical site infection 1/19 (5%)
Pathogens†
Pseudomonas aeruginosa 12/20 (60%)
Acinetobacter baumannii 5/20 (25%)
Klebsiella pneumoniae 2/20 (10%)
Enterobacter cloacae 1/20 (5%)
Mortality 7/17 (41%)
* The analysis of the site of infection was based on 19 episodes of infection in 17 patients.
† The analysis of the responsible pathogens was based on 20 isolates from 19 episodes of infection in 17 patients [two pathogens were isolated in 
one episode of pneumonia (Klebsiella pneumoniae + Acinetobacter baumannii mixed infection)].BMC Infectious Diseases 2005, 5:1 http://www.biomedcentral.com/1471-2334/5/1
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course for 4 days. The cause for the interruption of colistin
in these cases was the attending physicians' attempts to
obtain cultures without the confounding influence of
antimicrobial treatment in patients with puzzling contin-
uing symptoms of infection. The mean duration of colis-
tin administration (± SD), for each course of colistin
therapy was 43,4 days (± 14,6 days). The mean daily dos-
age ± SD for each course was 4.4 million IU (352 mg) ±
2.1 million IU (168 mg) and the mean cumulative dosage
of colistin ± SD for each course was 190.4 million IU
(15.232 mg) ± 91.0 million IU (7.280 mg). The mean
daily dosage for a patient with body weight of 70 kg was
62.857 IU/kg (5 mg/kg). For patients with impaired renal
function, dosage adjustments were done mainly after con-
sulting the ICU director or the Infectious Disease special-
ists of the hospital, based on the following protocol: if
serum creatinine level was 1.3–1.5 mg/dl, 1.6–2.5 mg/dl
or = 2.6 mg/dl, the dosage of colistin administered was 2
million IU (160 mg) every 12 hours, 24 hours, or 36
hours, respectively. Patients who were on dialysis treat-
ment received 1 million IU (80 mg) of colistin after dial-
ysis. Colistin was given for long duration in patients
mainly in the ICU setting, because of persistence of infec-
tions due to Gram-negative bacteria sensitive only to col-
istin or bacteria sensitive also to antibiotics of other
classes that were previously administered (based on in-
vitro susceptibility test results) but failed. Subsequently,
no other therapeutic strategy was considered better than
the continuation of colistin (as combination therapy or
monotherapy) because of failure of previous antibiotic
regimens and the lack of other therapeutic options.
The analysis of the responsible pathogens was based on
20 isolates from 19 episodes of infection in 17 patients
(two pathogens were isolated in one episode). In 2 epi-
sodes of infection, both caused by Pseudomonas aeruginosa
strains, the minimum inhibitory concentrations (MICs)
were not available. In the remaining 10 Pseudomonas aeru-
ginosa isolates, the MICs to colistin ranged from = 0.5 mg/
l to 2 mg/l. In vitro susceptibility testing for the 5 isolated
Acinetobacter baumannii strains revealed MICs to colistin =
0.5 mg/l, for the 2 Klebsiella pneumoniae strains MICs were
0.5 mg/l and 2 mg/l, and for the Enterobacter cloacae strain
MIC was 1 mg/l.
The all-cause in-hospital mortality was 41,2% (7 out of 17
patients). Clinical cure and improvement, defined as res-
olution and partial resolution, respectively, of presenting
symptoms and signs of the infection by the end of colistin
treatment was observed in 14 of the 19 episodes of infec-
tion (73.7%) [cure 10/19 episodes (52.6%), improve-
ment 4/19 episodes (21.1%)]. Unresponsiveness, defined
as persistence or worsening of presenting symptoms and/
or signs of the infection during intravenous colistin
administration, was observed in 5 of the 19 episodes of
infection (26.3%).
All patients had been admitted to the ICU at some time
during their hospitalisation. In 12 courses out of the 19
analyzed the whole colistin therapy was administered in
the ICU, in 1 course it was administered in a hospital
ward, and in 6 courses it was given both in the ICU and a
hospital ward.
Renal toxicity
Figure 1 depicts the box plots of serum creatinine and
blood urea values of patients on the first day of colistin,
the maximum values during the course of administration
of colistin, and the values at the end of the treatment with
colistin (one patient, who was on hemodialysis treatment
prior to and during the colistin course, was removed from
the analysis of the comparisons of the creatinine and urea
values). The median value of baseline creatinine at the
beginning of colistin therapy for the 18 prolonged courses
of colistin was 0,6 mg/dl. Compared to this value, there
was a slight increase of the median of values of creatinine
at the end of the colistin course by 0,1 mg/dl, without sta-
tistical significance (p = 0,67). The median of the maxi-
mum values of creatinine observed was 0,85 mg/dl and
was found to be statistically different from both the
median of start (p < 0,001) and end of treatment values (p
< 0,001). The maximum absolute increase of creatinine,
compared to baseline, observed in an episode was 1,4 mg/
dl. Only one patient had an increase of more than 50% of
the baseline creatinine level to a value higher than 1.3 mg/
dl at the end of colistin treatment. For the subgroup of 12
patients with 14 courses of prolonged colistin administra-
tion, with normal serum creatinine at the initiation of
treatment, the median serum creatinine values at baseline
and at the end of colistin treatment were 0,60 mg/dl and
0,55 mg/dl, respectively. In addition, the median maxi-
mum value of serum creatinine during the course of colis-
tin treatment was 0,80 mg/dl among this group of
patients.
At the initiation of colistin administration the median
value of baseline blood urea for the 18 courses was 42 mg/
dl. During the 18 prolonged courses of colistin adminis-
tration there was a slight increase in blood urea values; the
median maximum value was 60 mg/dl. However, at the
completion of colistin therapy median blood urea value
returned to 41 mg/dl.
During the 19 courses of colistin administration, other
potentially nephrotoxic drugs were given. Specifically,
aminoglycosides were co-administered in 12 courses
[median duration of co-administration (± SD) in these 12
courses 12,5 (± 16,8) days], teicoplanin in 10 [median
duration of co-administration 16,0 (± 9,0) days],BMC Infectious Diseases 2005, 5:1 http://www.biomedcentral.com/1471-2334/5/1
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vancomycin in 8 [median duration of co-administration
23,0 (± 11,2) days], amphotericin in 4 [median duration
of co-administration 8,0 (± 9,0) days].
Four patients had history of chronic renal dysfunction,
with only one of them receiving hemodialysis treatment
prior to admission. This patient continued the
The distribution of serum creatinine and blood urea levels on the 1st day of colistin treatment (start), at the peak value (max),  and the end of colistin treatment (end) in all studied courses of prolonged treatment with colistin Figure 1
The distribution of serum creatinine and blood urea levels on the 1st day of colistin treatment (start), at the peak value (max), 
and the end of colistin treatment (end) in all studied courses of prolonged treatment with colistin. (The horizontal line within 
the boxes represents the median creatinine or blood urea baseline value at the 1st day of colistin treatment. "Shaded" boxes in 
the figures represent the distribution of the laboratory values contained between the 25th and 75th percentiles (the interquartile 
range). Dotted lines (whisker lines) extend from the box, down and up, to the minimum and maximum values of the distribu-
tions that are not outliers (i.e. that are within 1.5 times the interquartile range); these values of the distribution are shown as 
"brackets". Any value, which is an outlier, is drawn as a "horizontal line").
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hemodialysis during his treatment with colistin and died
due to sepsis. For the other 3 patients the baseline, the
maximum, and the end-of-therapy creatinine values (mg/
dl), were 1,8/2,1/2,1 for the first patient, 3,7/3,7/2,4 for
the second patient and 2,4/3,8/2,3 for the third patient.
Only one patient had acute renal failure prior to colistin
use, which was due to severe haemorrhage during surgery.
This patient received 13 courses of hemodialysis. One day
after the last course, colistin therapy had to be initiated for
the management of Acinetobacter baumannii pneumonia,
sensitive only to colistin and gentamicin. Apart from a
slight elevation of serum creatinine (from 2,3 mg/dl to 2,7
mg/dl) on the 5th day of treatment no other sign of neph-
rotoxicity was observed during a 34-day administration of
colistin (the 9th day creatinine returned to 0,7 mg/dl).
Neuromuscular toxicity
No apnea or other evidence of neuromuscular blockade
was noted in any of these patients who received pro-
longed treatment with colistin. Four patients were clini-
cally diagnosed to have polyneuropathy and/or myopathy
before or during colistin treatment. In the first patient the
polyneuropathy symptoms appeared while she was on
her 25th day of colistin treatment and became worse on
the 27th day. From then on, and although colistin was
continued for 11 more days, the symptoms gradually sub-
sided. No confirmatory electromyographic testing was
performed. The second patient was transferred from
another ICU where he was diagnosed as having myopathy
due to sepsis. Fifteen days after his admission, and while
his myopathy was improving, therapy with colistin was
initiated; the treatment did not affect the gradual
improvement. An electromyography performed on his
21st day in our ICU, showed mild axial sensory-motor
polyneuropathy and myopathy. He received colistin for a
total of 52 days and made full recovery from his neuropa-
thy/myopathy during the course of colistin administra-
tion. The third patient developed ICU polyneuropathy
one week prior to colistin administration and, again,
recovered gradually from it while he was on colistin treat-
ment. The fourth patient was transferred from another
ICU, where he had developed ICU polyneuropathy. Only
this patient had moderate worsening of the neuropathy
while he was receiving colistin. Despite that, he received
colistin for a total of 35 days for a respiratory infection
with persisting Pseudomonas aeruginosa sensitive only to
colistin. His neuropathy improved gradually after the end
of colistin treatment. Thus, our assessment regarding
these 4 patients who experienced polyneuropathy and/or
myopathy is that colistin therapy was probably associated
with the development of neurotoxicity only in one of the
4 patients.
Liver and biliary tree toxicity
Data for the possible hepatobiliary toxicity of colistin
were collected. Both laboratory and clinical findings were
taken into consideration. In subgroup analyses of patients
for whom data were available, no substantial changes on
liver function tests was found, as described in Figure 2
(data for SGPT, alkaline phosphatase, direct and indirect
bilirubin are not shown). Three of our patients were
found to have increased levels of hepatic and cholestatic
enzymes during colistin administration. One of them was
found to have acute cholecystitis, the second had severe
inflammatory systemic reaction (SIRS), and the third had
transient elevation of transaminases while he was receiv-
ing anti-epileptic medications together with colistin.
Conclusions
The main finding of the study is that no significant deteri-
oration of renal function was found in patients with base-
line normal serum creatinine value during prolonged
administration of intravenous colistin. In addition, in the
group of patients with pre-existing chronic renal dysfunc-
tion (not on hemodialysis) the administration of the
medication for a long duration did not influence further
their renal function. The observed slight increase in the
serum creatinine values at the end of treatment (0,1 mg/
dl increase in the median creatinine values from the start
to end of colistin administration) cannot be attributed
only to the prolonged colistin administration as other fac-
tors such as concomitantly administered potential neph-
rotoxic agents, and sepsis per ce may have had an effect. In
addition, apnea or other evidence of neuromuscular
blockade was not observed in any of the 17 patients who
received prolonged treatment with colistin.
Early experience with colistin revealed a high incidence of
toxicity, mainly nephrotoxicity. In 1969, Ryan et al.
reported the fatal case of a previously healthy 4-year-old
child with persistent fever after appendectomy who died
due to cardiac arrest [10]. The child had received colistin
intramuscularly due to the growth of Pseudomonas aerugi-
nosa and E. coli strains from the excised specimen. This
patient developed acute tubular necrosis (confirmed by
autopsy) and apnea requiring intubation and mechanical
ventilation. However, in this case the dosage of colistin
used was 30 mg/kg of body weight every six hours (120
mg/kg/day) whereas the recommended dose is 2,5 – 5
mg/kg/day. One year later, several reports showed high
renal adverse reaction rates after colistin administration
[2,4,11]. In many of them the dosage used was also higher
compared to the recommended, i.e. 6,3 mg/kg/day in one
report, and 26 mega units in another administered as 10
mega units by intramuscular injection, 10 mega units by
intravenous injection and 6 mega units by inhalation (no
details are provided in the report about the ratio of IU of
colistin per mg). In addition, dosage adjustments inBMC Infectious Diseases 2005, 5:1 http://www.biomedcentral.com/1471-2334/5/1
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patients with renal dysfunction were not always followed,
as well as there were also other factors which perhaps con-
tributed to toxicity, such as the co-administration of other
medications with potential toxicity, including anesthetic
drugs and muscle relaxants.
However, recent data from published reports do not cor-
roborate this finding [14]. Notably, one study conducted
in 35 patients with ventilator-associated pneumonia due
to multidrug-resistant Acinetobacter baumannii, who
received either intravenous colistin (21 patients) or imi-
The distribution of liver function tests [SGOT (AST = aspartate aminotransferase), γ-GT, and total bilirubin] on the 1st day of  colistin treatment (start), at the peak value (max), and at the end of colistin treatment (end) in studied courses of prolonged  treatment with colistin Figure 2
The distribution of liver function tests [SGOT (AST = aspartate aminotransferase), γ-GT, and total bilirubin] on the 1st day of 
colistin treatment (start), at the peak value (max), and at the end of colistin treatment (end) in studied courses of prolonged 
treatment with colistin. (The horizontal line within the boxes represents the median creatinine or blood urea baseline value at 
the 1st day of colistin treatment. "Shaded" boxes in the figures represent the distribution of the laboratory values contained 
between the 25th and 75th percentiles (the interquartile range). Dotted lines (whisker lines) extend from the box, down and up, 
to the minimum and maximum values of the distributions that are not outliers (i.e. that are within 1.5 times the interquartile 
range); these values of the distribution are shown as "brackets". Any value, which is an outlier, is drawn as a "horizontal line").
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penem (14 patients), showed an almost double increase
in nephrotoxicity rates among the patients in the imi-
penem group compared to colistin group [12]. In addi-
tion, Stein et al. recently reported their experience from 3
patients with orthopedic infections who received colistin
for 3 – 6 months without developing any adverse effect
requiring discontinuation of the treatment [13].
The conclusion in the majority of the published studies
during 1960 – 1970 was that colistin must be used in seri-
ous infections where other antimicrobial agents have
failed, always with close monitor of renal function, and
with precaution in the co-administration of other possible
nephrotoxic or neutotoxic agents [2,4]. Subsequently, the
considerable difference regarding reporting toxicity of col-
istin between old and recent studies deserves an explana-
tion. First, the formulations of currently used colistin may
be more purified compared with the old ones. The experi-
ence that was accumulated from the use of vancomycin
may support this possibility. It is known that the concerns
about serious and/or common nephrotoxicity of vanco-
mycin overwhelmed the older literature. Second, fluid
supplementation and supportive treatment of severely ill
patients has been improved nowadays. Third, higher
doses of colistin were administered to patients during the
first years of its use.
Our study is not without limitations. It is a retrospective
study with the inherited problems related to this study
design, including difficulties in the determination of col-
istin associated sensory neurotoxicity. In addition, the
number of studied patients is relatively small and there is
no control group. However, our study offers insight
related to interesting experience from a group of patients
who received prolonged treatment with colistin for vari-
ous infections, mainly as a salvage treatment of persisting
and serious infections.
In conclusion, intravenous colistin seems to be a safe ther-
apeutic intervention for serious infections due to multid-
rug-resistant Gram-negative bacteria even when it is
administered for a prolonged duration (more than four
weeks). More studies will be needed to further clarify the
correct use of this old antibiotic in the 21st century.
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